Cellosaurus logo
expasy logo

Cellosaurus NB4 (CVCL_0005)

[Text version]
Cell line name NB4
Synonyms NB-4; NB.4
Accession CVCL_0005
Resource Identification Initiative To cite this cell line use: NB4 (RRID:CVCL_0005)
Comments Group: Patented cell line.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Part of: LL-100 blood cancer cell line panel.
Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2030.
Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1045.
Population: Caucasian.
Doubling time: 36-40 hours (PubMed=1995093); 30 hours (PubMed=25984343); ~35-45 hours (DSMZ=ACC-207).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Cell surface proteome.
Omics: CTCF ChIP-seq epigenome analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
Sequence variations
  • Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=12353268; PubMed=15843827).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*11:01,11:01
HLA-BB*35:01,40:01
HLA-CC*03:04,04:01

Source: CLS=300299
Class I
HLA-AA*11:01:01
HLA-BB*35:01:01,40:01:02
HLA-CC*03:04:01,04:01:01
Class II
HLA-DPDPB1*01:01:01,04:01:01
HLA-DQDQA1*01:01,03:01:01
DQB1*03:02,05:01:01
HLA-DRDRB1*01:01:01,04:04:01

Source: DSMZCellDive=ACC-207
Class I
HLA-AA*11:01:01,11:01:01
HLA-BB*35:01:01,40:01:02
HLA-CC*03:04:01,04:01:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African3.99
Native American0
East Asian, North4.75
East Asian, South0
South Asian0
European, North49.28
European, South41.98
Disease Acute promyelocytic leukemia with PML-RARA (NCIt: C3182)
Acute promyelocytic leukemia (ORDO: Orphanet_520)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_VV77 (NB4-A1)CVCL_U080 (NB4-AsR)CVCL_VV78 (NB4-B1)
CVCL_VV79 (NB4-D5)CVCL_U085 (NB4-DR1)CVCL_8811 (NB4-LR1)
CVCL_U086 (NB4-S1)CVCL_U083 (NB4.007/6)CVCL_U084 (NB4.306)
CVCL_U112 (NB4.437r)CVCL_U082 (NB4/As)CVCL_IY15 (NB4R)
Sex of cell Female
Age at sampling 23Y
Category Cancer cell line
STR profile Source(s): CLS; Cosmic-CLP; DSMZ; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,12
D2S133820,25
D3S135815,17
D5S81813
D7S82010,13
D8S117910,14
D13S31711,12
D16S5399
D18S5112,14
D19S43315
D21S1128,33.2
FGA21,22
Penta D10,13
Penta E7,13
TH017,9.3
TPOX8,11
vWA16,19

Run an STR similarity search on this cell line
Web pages https://www.proteinatlas.org/learn/cellines
http://genome.ucsc.edu/ENCODE/protocols/cell/human/NB4_protocol.pdf
Publications

PubMed=1995093; DOI=10.1182/blood.V77.5.1080.1080
Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., Berger R.
NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3).
Blood 77:1080-1086(1991)

PubMed=1453773
Duprez E., Ruchaud S., Houge G., Martin-Thouvenin V., Valensi F., Kastner P., Berger R., Lanotte M.
A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features.
Leukemia 6:1281-1287(1992)

PubMed=7630193
Bruel A., Benoit G., De Nay D., Brown S., Lanotte M.
Distinct apoptotic responses in maturation sensitive and resistant t(15;17) acute promyelocytic leukemia NB4 cells. 9-cis retinoic acid induces apoptosis independent of maturation and Bcl-2 expression.
Leukemia 9:1173-1184(1995)

Patent=US5589345
Lanotte M., Berger R.
Cultures of permanent lines of human promyelocytic cells and their uses for the screening of molecules utilizable in particular in the treatment of leukemias.
Patent number US5589345, 31-Dec-1996

PubMed=9737686; DOI=10.1038/sj.leu.2401112
Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., Takeshita K., Takeshita A., Ohno R.
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Leukemia 12:1383-1391(1998)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11704857; DOI=10.1038/sj.onc.1204863
Roussel M.J.S., Lanotte M.
Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes.
Oncogene 20:7287-7291(2001)

PubMed=12353268; DOI=10.1002/gcc.10117
Mozziconacci M.-J., Rosenauer A., Restouin A., Fanelli M., Shao W.-L., Fernandez F., Toiron Y., Viscardi J., Gambacorti-Passerini C., Miller W.H. Jr., Lafage-Pochitaloff M.
Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones.
Genes Chromosomes Cancer 35:261-270(2002)

PubMed=14504097; DOI=10.1182/blood-2003-02-0418
Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Sugita K., Ida K., Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=23955599; DOI=10.1038/ng.2731
Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y., Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S., Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D., Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K., Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M., Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S., Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H., Haferlach T., Shirahige K., Miyano S., Ogawa S.
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Nat. Genet. 45:1232-1237(2013)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) CLS; 300299
DSMZ; ACC-207
NCBI_Iran; C515
Ubigene; YC-C122
Cell line databases/resources CLO; CLO_0007947
MCCL; MCC:0000350
CLDB; cl3643
cancercelllines; CVCL_0005
Cell_Model_Passport; SIDM00428
Cosmic-CLP; 1323913
DepMap; ACH-000294
DSMZCellDive; ACC-207
LINCS_LDP; LCL-1084
Lonza; 749
Anatomy/cell type resources BTO; BTO:0002136
Biological sample resources BioSample; SAMN03470835
BioSample; SAMN10988571
ENCODE; ENCBS032SIL
ENCODE; ENCBS259AAA
ENCODE; ENCBS390ENC
CRISP screens repositories BioGRID_ORCS_Cell_line; 212
Chemistry resources ChEMBL-Cells; CHEMBL3308423
ChEMBL-Targets; CHEMBL614188
GDSC; 1323913
PharmacoDB; NB4_990_2019
PubChem_Cell_line; CVCL_0005
Encyclopedic resources Wikidata; Q54907527
Experimental variables resources EFO; EFO_0002798
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM236798
GEO; GSM236834
GEO; GSM472929
GEO; GSM510512
GEO; GSM510513
GEO; GSM887349
GEO; GSM888426
GEO; GSM945252
GEO; GSM945275
GEO; GSM749716
GEO; GSM1022643
GEO; GSM1374696
GEO; GSM1374697
GEO; GSM1446740
GEO; GSM1670151
Polymorphism and mutation databases Cosmic; 787463
Cosmic; 850391
Cosmic; 922661
Cosmic; 924050
Cosmic; 975285
Cosmic; 981582
Cosmic; 996313
Cosmic; 1012107
Cosmic; 1037664
Cosmic; 1070692
Cosmic; 1078721
Cosmic; 1089522
Cosmic; 1127257
Cosmic; 1181601
Cosmic; 1523826
Cosmic; 1524838
Cosmic; 1601063
Cosmic; 1604862
Cosmic; 1779130
Cosmic; 2036677
Cosmic; 2089653
Cosmic; 2131548
Cosmic; 2306227
Cosmic; 2579202
IARC_TP53; 21530
IARC_TP53; 21705
LiGeA; CCLE_910
Progenetix; CVCL_0005
Proteomic databases PRIDE; PXD000589
PRIDE; PXD001610
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number43